Chrome Extension
WeChat Mini Program
Use on ChatGLM

Infliximab in Young Paediatric IBD Patients: It is All about the Dosing

Global Pediatric Health(2020)SCI 2区

Erasmus Medical CenterSophia Children’s Hospital | University of Alberta | Hôpital Necker-Enfants-Malades | Our Lady’s Children’s Hospital and RCSI | University of Helsinki | University Hospital Motol | Tel Aviv University | Shaare Zedek Medical Center | Universitair Ziekenhuis | Erasmus Medical Center | Amsterdam UMC - Vrije UniversiteitEmma Children’s Hospital | Utrecht Medical CenterWilhelmina Children’s Hospital | Hôpital Robert Debré

Cited 46|Views86
Abstract
Infliximab (IFX) is administered intravenously using weight-based dosing (5 mg/kg) in inflammatory bowel disease (IBD) patients. Our hypothesis is that especially young children need a more intensive treatment regimen than the current weight-based dose administration. We aimed to assess IFX pharmacokinetics (PK), based on existing therapeutic drug monitoring (TDM) data in IBD patients < 10 years. TDM data were collected retrospectively in 14 centres. Children treated with IFX were included if IFX was started as IBD treatment at age < 10 years (young patients, YP) and PK data were available. Older IBD patients aged 10–18 years were used as controls (older patients, OP). Two hundred and fifteen paediatric inflammatory bowel disease (PIBD) patients were eligible for the study (110 < 10 year; 105 ≥ 10 years). Median age was 8.3 years (IQR 6.9–8.9) in YP compared with 14.3 years (IQR 12.8–15.6) in OP at the start of IFX. At the start of maintenance treatment, 72% of YP had trough levels below therapeutic range (< 5.4 μg/mL). After 1 year of scheduled IFX maintenance treatment, YP required a significantly higher dose per 8 weeks compared with OP (YP; 9.0 mg/kg (IQR 5.0–12.9) vs. OP; 5.5 mg/kg (IQR 5.0–9.3); p < 0.001). The chance to develop antibodies to infliximab was relatively lower in OP than YP (0.329 (95% CI − 1.2 to − 1.01); p < 0.001), while the overall duration of response to IFX was not significantly different (after 2 years 53% ( n = 29) in YP vs. 58% ( n = 45) in OP; p = 0.56). Conclusion : Intensification of the induction scheme is suggested for PIBD patients aged < 10 years. What is Known? •Infliximab trough levels of paediatric IBD patients are influenced by several factors as dosing scheme, antibodies and inflammatory markers. •In 4.5–30% of the paediatric IBD patients, infliximab treatment was stopped within the first year. What is New? •The majority of young PIBD (< 10 years) have inadequate IFX trough levels at the start of maintenance treatment. •Young PIBD patients (< 10 years) were in need of a more intensive treatment regimen compared with older paediatric patients during 1 year of IFX treatment. •The chance to develop antibodies to infliximab was relatively higher in young PIBD patients (< 10 years).
More
Translated text
Key words
Crohn's disease,Ulcerative colitis,Anti-TNF,Clinical pharmacology,Paediatric,Gastroenterology,Biologics
PDF
Bibtex
AI Read Science
AI Summary
AI Summary is the key point extracted automatically understanding the full text of the paper, including the background, methods, results, conclusions, icons and other key content, so that you can get the outline of the paper at a glance.
Example
Background
Key content
Introduction
Methods
Results
Related work
Fund
Key content
  • Pretraining has recently greatly promoted the development of natural language processing (NLP)
  • We show that M6 outperforms the baselines in multimodal downstream tasks, and the large M6 with 10 parameters can reach a better performance
  • We propose a method called M6 that is able to process information of multiple modalities and perform both single-modal and cross-modal understanding and generation
  • The model is scaled to large model with 10 billion parameters with sophisticated deployment, and the 10 -parameter M6-large is the largest pretrained model in Chinese
  • Experimental results show that our proposed M6 outperforms the baseline in a number of downstream tasks concerning both single modality and multiple modalities We will continue the pretraining of extremely large models by increasing data to explore the limit of its performance
Try using models to generate summary,it takes about 60s
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Related Papers

[Timing of Food Introduction to the Infant Diet and Risk of Food Allergy: a Systematic Review and Meta-analysis].

N,X Y Li, S Wang, J,Y J Gao,Z L Li
Zhonghua er ke za zhi = Chinese journal of pediatrics 2021

被引用3

Data Disclaimer
The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn
Chat Paper

要点】:本研究通过回顾性分析14个中心的14岁以下炎症性肠病(IBD)患者的英夫利西单抗(IFX)治疗数据,评估了IFX的药代动力学(PK),发现小于10岁的年轻IBD患者比10-18岁的患者需要更密集的治疗方案,PK数据支持这一结论。

方法】:研究采用了回顾性分析,利用现有的治疗药物监测(TDM)数据来评估PK。

实验】:实验在14个中心进行,纳入了225名PIBD患者,其中110名小于10岁,105名大于等于10岁。结果显示,小于10岁的年轻患者在维持治疗开始时,有72%的谷浓度低于治疗范围,而经过一年的标准IFX维持治疗后,他们需要的剂量显著高于年长患者。此外,年轻患者产生抗IFX抗体的几率更高,但IFX的整体响应持续时间无显著差异。